

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

APC/Cyanine7 anti-human HLA-DR

RRID:AB_493586

Type: Antibody

Proper Citation

BioLegend Cat# 307618, RRID:AB_493586

Antibody Information

URL: http://antibodyregistry.org/AB_493586

Proper Citation: BioLegend Cat# 307618, RRID:AB_493586

Target Antigen: HLA-DR

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC/Cyanine7 anti-human HLA-DR

Description: This monoclonal targets HLA-DR

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone L243

Antibody ID: AB_493586

Vendor: BioLegend

Catalog Number: 307618

Alternative Catalog Numbers: 307617

Record Creation Time: 20250819T234643+0000

Record Last Update: 20250820T062324+0000

Ratings and Alerts

No rating or validation information has been found for APC/Cyanine7 anti-human HLA-DR.

No alerts have been found for APC/Cyanine7 anti-human HLA-DR.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. STAR protocols, 6(2), 103742.

Wang R, et al. (2025) An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B ?1/2 shedding. Cell reports. Medicine, 6(3), 101981.

Li YR, et al. (2025) Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell reports. Medicine, 6(9), 102321.

Lee H, et al. (2025) TCR signaling via NFATc1 constrains IL-15-induced bystander activation of human memory CD8+ T cells. Immunity, 58(12), 2957.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med (New York, N.Y.), 100804.

Zhong L, et al. (2025) Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell, 188(4), 1119.

Arbués A, et al. (2025) Soluble immune mediators orchestrate protective in vitro granulomatous responses across Mycobacterium tuberculosis complex lineages. eLife, 13.

Wang Y, et al. (2024) Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. Cell reports. Medicine, 5(1), 101374.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell, 187(26), 7470.

DuCote TJ, et al. (2024) EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas. Cancer research communications, 4(2), 388.

Reinstein ZZ, et al. (2024) Preexisting Skin-Resident CD8 and ?? T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy. Cancer discovery, 14(9), 1631.

Laliberté A, et al. (2023) Vpr attenuates antiviral immune responses and is critical for full pathogenicity of SIVmac239 in rhesus macaques. *iScience*, 26(12), 108351.

Sureshchandra S, et al. (2023) Multimodal profiling of term human decidua demonstrates immune adaptations with pregravid obesity. *Cell reports*, 42(7), 112769.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. *iScience*, 26(10), 107952.

Lewis SA, et al. (2023) Chronic alcohol consumption dysregulates innate immune response to SARS-CoV-2 in the lung. *EBioMedicine*, 97, 104812.

Prokhnevskaya N, et al. (2023) CD8⁺ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. *Immunity*, 56(1), 107.

Nixon BG, et al. (2022) Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. *Immunity*, 55(11), 2044.

Jung S, et al. (2022) The generation of stem cell-like memory cells early after BNT162b2 vaccination is associated with durability of memory CD8⁺ T cell responses. *Cell reports*, 40(4), 111138.

, et al. (2022) A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. *Cell*, 185(5), 916.

Shen Q, et al. (2022) A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms. *Cancer research communications*, 2(4), 258.